Abhijit Akella

First, on the gross margin expansion. So is this entirely because of the shift in product mix within the Pharma catalog business? Or have there been improvement in process efficiencies, et cetera, also in that business?

Okay. So the solar contribution is now fully in the base, is it? Or was it only partial for the quarter and we see the full impact in subsequent quarters?

Got it. Just one further clarification on that margin topic. So Abhishek bhai, we have seen in the past that we used to enjoy 20% plus margins on the pharma side a few years back. And then there was some erosion that happened because of maybe Chinese competition and increasing raw material prices, et cetera. Now we have managed to claw it back.